Literature DB >> 26551633

Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States.

Jane Apperley1, Dietger Niederwieser2, Xiao-Jun Huang3, Arnon Nagler4, Ephraim Fuchs5, Jeff Szer6, Yoshihisa Kodera7.   

Abstract

One of the major projects of the Worldwide Network for Blood and Marrow Transplantation (WBMT) is to promote hematopoietic stem cell transplantation (HSCT) in emerging countries in the world. For these countries, HLA haploidentical HSCT (haplo-HSCT) from family members is an attractive approach because of its cost effectiveness. To learn the current status, including recent trends, of haplo-HSCT, the WBMT invited speakers from major transplant centers in 3 regions (Asia, Europe, and North America) to present at its annual WBMT Joint Session. This article represents the direct reports from these 3 speakers in addition to introductions by 2 WBMT speakers who address data from the Global Transplant Activity survey. It must be emphasized, however, that certain promising results of haplo-HSCT presented in this article were obtained at well-experienced institutes.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Beijing Protocol; Europe; Global Activity Survey; Haplo-HSCT; Haplo-transplantation; United States

Mesh:

Year:  2015        PMID: 26551633     DOI: 10.1016/j.bbmt.2015.11.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  25 in total

Review 1.  Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection.

Authors:  Katharina Fleischhauer; Katharine C Hsu; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-05-24       Impact factor: 5.483

2.  Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome.

Authors:  P R Geethakumari; B Leiby; R Nair; S O Alpdogan; M Carabasi; J Filicko-O'Hara; S Gaballa; M Kasner; T Klumpp; U Martinez-Outschoorn; N Palmisiano; J L Wagner; P Porcu; N Flomenberg; D Grosso
Journal:  Bone Marrow Transplant       Date:  2017-07-31       Impact factor: 5.483

3.  Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia.

Authors:  R Zhang; W Shi; H-F Wang; Y You; Z-D Zhong; W-M Li; C Zhang; X Lu; Y-D Wang; P Zheng; J Fang; M Hong; Q-L Wu; L-H Xia
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

Review 4.  Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Frédéric Baron; Mohamad Mohty; Didier Blaise; Gérard Socié; Myriam Labopin; Jordi Esteve; Fabio Ciceri; Sebastian Giebel; Norbert Claude Gorin; Bipin N Savani; Christoph Schmid; Arnon Nagler
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

5.  Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes.

Authors:  Yu Wang; Ying-Jun Chang; Lu Chen; Lan-Ping Xu; Zhi-Lei Bian; Xiao-Hui Zhang; Chen-Hua Yan; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Oncoimmunology       Date:  2017-09-14       Impact factor: 8.110

6.  Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.

Authors:  A Gratwohl; A Sureda; J Cornelissen; J Apperley; P Dreger; R Duarte; H T Greinix; E Mc Grath; N Kroeger; F Lanza; A Nagler; J A Snowden; D Niederwieser; R Brand
Journal:  Leukemia       Date:  2017-03-08       Impact factor: 11.528

7.  Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.

Authors:  Bronwen E Shaw
Journal:  Blood Adv       Date:  2017-02-14

8.  Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis.

Authors:  Emi Yokoyama; Daigo Hashimoto; Eiko Hayase; Takahide Ara; Reiki Ogasawara; Shuichiro Takahashi; Hiroyuki Ohigashi; Takahiro Tateno; Yuta Hasegawa; Xuanzhong Chen; Takanori Teshima
Journal:  Bone Marrow Transplant       Date:  2019-11-04       Impact factor: 5.483

Review 9.  NK cell therapy for hematologic malignancies.

Authors:  Rohtesh S Mehta; Brion Randolph; May Daher; Katayoun Rezvani
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

10.  NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.

Authors:  Antonio Russo; Giacomo Oliveira; Sofia Berglund; Raffaella Greco; Valentina Gambacorta; Nicoletta Cieri; Cristina Toffalori; Laura Zito; Francesca Lorentino; Simona Piemontese; Mara Morelli; Fabio Giglio; Andrea Assanelli; Maria Teresa Lupo Stanghellini; Chiara Bonini; Jacopo Peccatori; Fabio Ciceri; Leo Luznik; Luca Vago
Journal:  Blood       Date:  2017-10-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.